Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,163 matching trials from the live ClinicalTrials.gov search.
Conditions
Venous Thromboembolism (VTE)
Interventions
Betrixaban, Enoxaparin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
7,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
Conditions
Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Escondido, California • New Haven, Connecticut • Columbus, Georgia + 19 more
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Conditions
Alopecia Areata
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Asthma
Interventions
MEDI528 30 mg, MEDI528 100 mg, MEDI528 300 mg, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
24
States / cities
Pell City, Alabama • Los Angeles, California • Sacramento, California + 21 more
Conditions
Temporomandibular Disorders
Interventions
Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of RGLS8429 in Healthy Volunteers

NCT05429073
Conditions
Healthy Volunteers
Interventions
RGLS8429, Placebo volume-matching RGLS8429 dose
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Achondroplasia
Interventions
Navepegritide, Placebo for Navepegritide
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
0 Years to 2 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin
Conditions
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 54 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
72
States / cities
Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more
Conditions
Acromegaly
Interventions
IONIS-GHR-LRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 3 more
Conditions
Alcohol Use Disorder
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
19
States / cities
Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more
Conditions
Hidradenitis Suppurativa
Interventions
Imsidolimab, Placebo
Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Fountain Valley, California • Northridge, California + 14 more
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase1 Study of VIB9600

NCT03621605
Conditions
Safety Issues
Interventions
VIB9600, Placebos
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)

NCT02187172
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Ustekinumab, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Osteogenesis Imperfecta
Interventions
Teriparatide (FORTEO), Placebos
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Portland, Oregon • Houston, Texas
Conditions
Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Interventions
taldefgrobep alfa, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 21 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more
Conditions
Giant Cell Arteritis
Interventions
Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
Conditions
Healthy
Interventions
PF-07314470, Placebo for PF-07314470
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
SAR156597, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more
Conditions
Alzheimer's Disease
Interventions
Placebo, Gantenerumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
30
States / cities
Sun City, Arizona • Tucson, Arizona • Costa Mesa, California + 27 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT00608062
Conditions
Arterial Stiffening, Aging, Menopause
Interventions
GnRHant - Ganirelix acetate, Transdermal estradiol patch, Transdermal placebo patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Type 1 Diabetes (T1D)
Interventions
Golimumab, Placebo (matching golimumab)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years to 44 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Thyroid Eye Disease, TED
Interventions
MHB018A, MHB018A placebo
Drug
Lead sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Coral Gables, Florida